This policy outlines how physicians can request access to Basilea’s investigational products under programs like Expanded Access, Named-Patient Supply, or Compassionate Use.
Basilea Pharmaceutica reported 2012 financial results, including CHF 344.0 million in liquidity and a reduced annual loss of CHF 53.0 million. CFO Joachim Blatter left the company, and CEO Ronald Scott took over interim CFO duties.
A shareholder of Basilea Pharmaceutica, HBM Healthcare Investments (Cayman) Ltd., proposed repayment of CHF 5.00 per share from the company’s capital contribution reserve, totaling approximately CHF 48 million.
In response to the growing public demand for transparency about interactions between the pharmaceutical industry and Healthcare Professionals (HCPs) / Healthcare Organizations (HCOs), the European Federation of Pharmaceutical Industries and Associations (EFPIA) issued a Disclosure Code in 2014.